Yunusbaeva, M.,
Borodina, L.,
Alekseev, P.,
Davydov, R.,
Sharipov, R.,
Bilalov, F.,
Yunusbayev, B. (2019) treatment success. We found that most of the MDR isolates from our patients were resistant to all
first-line for the loss of functional cardiomyocytes and improve the impaired heart functions.
First, residual
Dobrodeeva, V.S.,
Shnayder, N.A.,
Novitsky, M.A.,
Asadullin, A.R.,
Vaiman, E.E.,
Petrova, M.M.,
Limankin, O.V.,
Neznanov, N.G.,
Garganeeva, N.P.,
Nasyrova, R.F. (2022) weight of more than 6% since the start of APs
therapy. Group 2 comprised 74 patients with SSDs taking APs
Bikkuzin, T.,
Shi, Y.,
Sun, B.,
Guo, Y.,
Jin, X.,
Han, Z.,
V.N. Pavlov,
Zhang, H. (2019) A human corneal stroma induced pluripotent stem cell (HMUi001-A)
line was created from primary
therapy in the development of these cerebrovascular complications, which can occur at various stages